Negma is the fourth-largest independent integrated pharmaceutical group in France. For the most recent fiscal year it had sales of $150 million. Negma is a research-based company with 172 patents and leading positions in the osteoarthritisrheumatology, phlebotonic and the arterial hypertension segments. Wockhardt intends to use the patents to extend its business to other European markets.
At the agreed price of $265 million, Negma is valued at 1.8 times sales and 9.7 times Ebitda.
The acquisition makes Wockhardt the largest Indian pharmaceutical company in Europe with more...
¬ Haymarket Media Limited. All rights reserved.
